Edwards Lifesciences (NYSE:EW) SVP Sells $49,536.64 in Stock

Edwards Lifesciences Corporation (NYSE:EW) SVP Andrew Dahl sold 544 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE EW traded up $0.65 during trading hours on Monday, hitting $90.86. The company had a trading volume of 4,047,490 shares, compared to its average volume of 4,695,761. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $89.54 and its 200-day moving average is $85.08. The stock has a market capitalization of $52.32 billion, a P/E ratio of 52.22, a price-to-earnings-growth ratio of 2.37 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the stock. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences in the 1st quarter valued at about $25,000. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. Finally, Pin Oak Investment Advisors Inc. acquired a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $26,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Citigroup lifted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Truist Financial boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Mizuho raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.